Ensuring timely antibody supply during the COVID-19 pandemic - contact us for solutions

Goat F(ab')2 Anti-Human Ig-FITC

Cat. No.:
2012-02
Goat F(ab')2 Anti-Human Ig-FITC antibody for use in flow cytometry and immunohistochemistry assays.
$75.00
Size Price (USD) Quantity
0.5 mg $75.00
More Information
Isotype Goat F(ab')2 IgG
Isotype Control Goat F(ab')2 IgG-FITC
Specificity Reacts with the heavy and light chains of human IgG, IgM, and IgA
Source Pepsin digest of Goat Anti-Human Ig (SB Cat. No. 2010)
Cross Adsorption None; may react with immunoglobulins from other species
Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide
Clonality Polyclonal
Concentration 0.5 mg/mL
Volume 1.0 mL
Recommended Storage 2-8°C; Avoid exposure to light
Applications Quality tested applications for relevant formats include -
ELISA 1,2,5
FLISA
Flow Cytometry 7,8

Other referenced applications for relevant formats include -
ELISpot 3,4
Immunohistochemistry-Frozen Sections 6
Stimulation 9,10
RRID Number AB_2795573

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view


Need help with this product?
or call 800.722.2255
  1. 1. Kozlowski PA, Chen D, Eldridge JH, Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:813-22. (ELISA)
  2. 2. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
  3. 3. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. Int Immunol. 2009;21:1013-23. (ELISpot)
  4. 4. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. (ELISpot)
  5. 5. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193:5933-50. (ELISA)
  6. 6. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (IHC-FS)
  7. 7. Heile JM, Fong Y, Rosa D, Berger K, Saletti G, Campagnoli S, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol. 2000;74:6885-92. (FC)
  8. 8. Bao G, Li Y, Ma Q, He X, Xing J, Yang X, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther. 2005;4:1374-80. (FC)
  9. 9. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013;40:111-21. (Stim)
  10. 10. Lyubchenko T, Zerbe GO. B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One. 2014;9(7):e102128. (Stim)
See All References